Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Arbutus Biopharma Corp. sell geldnutzer

Start price
€5.25
25.07.20 / 50%
Target price
€2.00
13.10.20
Performance (%)
-47.37%
End price
€2.76
13.10.20
Summary
This prediction ended on 13.10.20 with a price of €2.76. The SELL prediction by geldnutzer for Arbutus Biopharma Corp. performed very well with a performance of -47.37%. geldnutzer has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Arbutus Biopharma Corp. 2.790% 2.790% -15.639% -15.788%
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

According to geldnutzer what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?

Pros
Differentiated customer and product portfolio
Could be worthwhile Investment >10% per year
Innovative
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Capable Management
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Standard Investments for future growth
Cons
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
very negative Cash Flow expected
Bad rating
Sustainability is little important
Higher risks for its business
Below average Marketposition
Significant cyclical dependencies
Risky balance sheet
ROE lower than 10% per year
Bad culture
Few uniques
Growths slower than the competition
Little known brand
Increased challenges to pay loans and raise capital

Comments by geldnutzer for this prediction

In the thread Arbutus Biopharma Corp. diskutieren
Prediction Sell
Perf. (%) -47.37%
Target price 3.000
Change
Ends at 13.10.20

Sell mit Kursziel 3,0

Prediction Sell
Perf. (%) -47.37%
Target price 2.000
Change
Ends at 13.10.20

Kursziel geändert auf 2,0

In the thread Trading Arbutus Biopharma Corp.
Prediction Sell
Perf. (%) -47.37%
Target price 2.000
Change
Ends at 13.10.20

Sell beendet

Stopped prediction by geldnutzer for Arbutus Biopharma Corp.

buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.80
19.11.22
€2.00
19.11.23
-41.00%
20.11.23

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.05
20.09.22
€1.80
20.09.23
36.59%
19.11.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.39
03.08.22
€2.80
03.08.23
-14.19%
20.09.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.37
28.04.22
€2.00
28.04.23
0.74%
03.08.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€3.03
11.11.21
€2.90
11.11.22
-21.78%
28.04.22

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.45
10.07.21
€1.90
10.07.22
23.96%
11.11.21

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.75
19.11.20
€2.90
19.11.21
-11.05%
10.07.21

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.53
28.10.20
€2.10
04.11.21
8.70%
19.11.20

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.76
13.10.20
€2.90
28.10.20
-8.43%
28.10.20

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€18.72
02.10.14
€25.17
09.10.14
-9.24%
09.10.14

Differentiated customer and product portfolio
Lower EBIT Margin than peer group
High valuation
Very low/no dividend yield expected